Verrica Pharmaceuticals Inc. (VRCA) on Track to Reach $19.00 in a Year

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is -30.71% lower on its value in year-to-date trading and has touched a low of $6.79 and a high of $18.67 in the current 52-week trading range. The VRCA stock was last observed hovering at around $14.07 in the last trading session, with the day’s loss setting it -3.06% off its average median price target of $19.00 for the next 12 months. It is also 68.54% off the consensus price target high of $35.00 offered by 6 analysts, but current levels are 35.24% higher than the price target low of $17.00 for the same period.

The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.


Currently trading at $11.01, the stock is -14.57% and -6.86% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.36 million and changing -21.75% at the moment leaves the stock -16.67% off its SMA200. VRCA registered -10.20% loss for a year compared to 6-month loss of -28.13%. The firm has a 50-day simple moving average (SMA 50) of $12.11 and a 200-day simple moving average (SMA200) of $12.65.

The stock witnessed a -4.26% gain in the last 1 month and extending the period to 3 months gives it a 0.73%, and is -27.18% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.10% over the week and 10.29% over the month.

Distance from 52-week low is 62.15% and -41.03% from its 52-week high.

Verrica Pharmaceuticals Inc. (VRCA) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Verrica Pharmaceuticals Inc. (VRCA) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.60, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Verrica Pharmaceuticals Inc. is expected to release its quarterly report on 08/05/2020 and quarterly earnings per share for the current quarter are estimated at -$0.47.The EPS is expected to shrink by -41.60% this year.

Verrica Pharmaceuticals Inc. (VRCA) Top Institutional Holders

82 institutions hold shares in Verrica Pharmaceuticals Inc. (VRCA), with 12.63M shares held by insiders accounting for 48.92% while institutional investors hold 69.75% of the company’s shares. The shares outstanding are 24.96M, and float is at 9.85M with Short Float at 5.28%. Institutions hold 35.63% of the Float.

The top institutional shareholder in the company is Perceptive Advisors Llc with over 3.41 million shares valued at $37.28 million. The investor’s holdings represent 13.21% of the VRCA Shares outstanding. As of Mar 30, 2020, the second largest holder is Orbimed Advisors LLC. with 1.48 million shares valued at $16.17 million to account for 5.73% of the shares outstanding. The other top investors are Blackrock Inc. which holds 0.73 million shares representing 2.82% and valued at over $7.97 million, while FMR, LLC holds 2.46% of the shares totaling 0.64 million with a market value of $6.95 million.

Verrica Pharmaceuticals Inc. (VRCA) Insider Activity

A total of 0 insider transactions have happened at Verrica Pharmaceuticals Inc. (VRCA) in the last six months, with sales accounting for 0 and purchases happening 0 times.

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free